metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Epithelioid granulomas in a patient with hepatitis C virus
Información de la revista
Vol. 1. Núm. 2.
Páginas 91-93 (abril - junio 2002)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Visitas
1426
Vol. 1. Núm. 2.
Páginas 91-93 (abril - junio 2002)
Open Access
Epithelioid granulomas in a patient with hepatitis C virus
Visitas
1426
Raúl Pichardo-Bahena1,*, Nahum Méndez-Sánchez2
1 Department of Pathology
2 Biomedical Research and The Liver Unit
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (2)
Tablas (2)
Table I. List of the etiologies of granulomas.*
Table II. List of the drugs causing granulomas.**
Mostrar másMostrar menos
Abstract

Hepatitis C virus infection causes an epidemic disease. The morphologic aspects of hepatitis C infection (HCV) are well established with regards to necroinflammatory processes and consequences like fibrosis, cirrhosis, and related neoplasms. However, the presence of epithelioid granulomas has not been well described for this infection. We report a patient with HCV and granulomas without any other co-infection or history of drug abuse.

Key words:
Hepatitis C
granulomas tuberculosis
Texto completo
Introduction

Cases of granulomatous hepatitis are well characterized in terms of their infective and idiopathic etiology and association with drugs and HIV co-infection.1-3 Etiologically, granulomas may be infective or non-infective. The infective causes include bacteria, fungi, mycobacteria, and viruses (Table I) In the non-infective types, the causes may be sarcoidosis, drugs or idiopathic (Table II) The drug causes include non-steroidal anti-inflammatory drugs, antibiotics, contrast medium, anti-convulsive agents, and drugs used for treatment of HCV infection. Thus, there is an extensive spectrum of etiologies.

Table I.

List of the etiologies of granulomas.*

Actinomycosis  Leprosy 
Adenoma, liver cell  Leukemia, hairy cell 
Alcoholic fatty liver  Listeriosis 
Ascariasis  Lymphoma, Hodgkin’s and non-Hodgkin’s 
Bacterial sepsis  Melioidosis 
Boutonneus fever  Mucolipidosis II 
Brucellosis  Mycobacterium avium-intracellulare infection 
Candidiasis  Nocardiosis 
Cat-scratch disease  Nonalcoholic steatohepatitis (secondary to jejunoileal bypass) 
Chronic granulomatous disease of childhood  Nonspecific reactive hepatitis 
Coccidioidomycosis  Paracoccidioidomycosis 
Cryptococcosis  Penicilliosis 
Cytomegalovirus infection  Polyarteritis nodosa 
Drugs/toxins  Primary biliary cirrhosis 
Eosinophilic gastroenteritis  Q fever 
Epstein-Barr virus infection  Rheumatoid arthritis 
Farber’s lipogranulomatosis  Salmonellosis 
Fascioliasis  Sarcoidosis 
Foreing body giant cell reaction  Schistosomiasis 
Hepatocellular cercinoma, fibrolamellar type  Syphilis, congenital, secondary and tertiary 
Histoplasmosis  Systemic lupus erythematosus 
Hydatid cyst  Toxoplasmosis 
Idiopathic granulomatous hepatitis  Tuberculosis 
Inflammatory pseudotumor  Visceral larva migrans 
Langherhan’s cell histiocytosis  Whipple’s disease 
Leishmaniasis  Zygomycosis 
*

From Kanel GC, Korula J: Granulomas, in Kanel and Korula, Liver Biopsy Evaluation. Philadelphia, Penn, Saunders 2000, p 43.

Table II.

List of the drugs causing granulomas.**

Allopurinol  Dimethicone  Oxacillin  Ranitidine 
Alpha-methyldopa  Disopyramida  Oxyophenbutaz-one  Silica 
Aspirin  Feprazone  Oxiphenisatin  Succinylsulfathiazole 
Bacille Calmette-Guerin therapy or vaccination  Glibenclamide  Papaverine  Sulfadiazine 
Barium  Gold sodium thiomalate  Penicillin  Sulfadimehoxine 
Beryllium  Gree-lipped mussel  Phenazone  Sulfadoxine-pyrimethamine 
Carbamazepine  Halogenated hydrocarbons  Phenprocoumon  Sulfanilamide 
Carbutamide  Isoniazid  Phenylbutazone  Sulfasalazine 
Cephalexin  Mestranol  Polyvinyl pyrrolidone  Sulfonamides 
Chlorpromazine  Metolazone  Prajmalium  Sulfonylurea agents 
Chlorpropamide  Mineral oil  Procainamide  Thorotrast (thorium dioxide) 
Copper  Nitrofurantoin  Procarbazine  Tocainide 
Dapsone  Norethyndrone  Pronestyl  Tolbutamide 
Diazepam  Norethynofrel  Quinidine  Trichlormethiazide 
Diltiazem  Norgestrel  Quinine  Trimethroprim-sulfamethoxazoleAllopurinol 
**

From Kanel GC, Korula J: Granulomas, in Kanel and Korula Liver Biopsy Evaluation. Philadelphia, Penn, Saunders 2000, p 221.

Case report

A 40-year-old male Mexican was admitted to hospital for evaluation of hypertransaminasemia (alanine aminotransaminase 63 U/L; aspartate aminotransferase 40 U/L) and painful neck and shoulders. Chronic active hepatitis caused by the hepatitis C virus was diagnosed. Serum HCV RNA concentration was 1,000,000 copies/mL, and the viral genotype was 1b. Further examination was instituted because of the simultaneous finding of granulomas in a liver biopsy. The patient did not give a history of any use of intravenous drugs and we found no other co-infections by laboratory tests.

Discussion

The morphological aspects of HCV infection have been described during the past three decades.4-8 These differing morphological and clinical diseases were first reported as non-A, non-B hepatitis.9-11 In 1989, the viral agent, HCV, was identified and isolated,12,13 and almost all cases of non-A non-B hepatitis were related to this viral agent. Most histopathological changes have been described following percutaneous or transjugular biopsies.

The histopathological changes are reported according to the hepatic area affected: the portal and periportal areas and the hepatic parenchyma. The disease is described in terms of the duration of chronic hepatitis, with activity in different grades,7,14,15 steatosis and fibrosis. The spectrum of histological changes is related to the degree of lymphocyte or lymphoplasmocyte infiltration into the liver, and to the necroinflammatory damage caused. The pathological and pharmacological investigations aim to evaluate the fibrosis and arrest it.

How can we explain the prevalence of granulomas in clinical hepatitis C? This is an item not well described for these patients, because publications have not identified granulomas in liver biopsies of patients with HCV, by Tru-cut needle, trans-jugular or open biopsies. However, other investigators have reported granulomas in patients with HCV infection without any other infectious agent, such as in liver-transplant patients with viral flare-ups16 and following HIV infection.

Only a few articles have mentioned the presence of epithelioid granulomas in the spectrum of chronic inflammation in patients with HCV.17 Morphologically, granulomas are associated with central necrosis surrounded by a rim of lymphocytes, similar to that observed in cases of tuberculosis. This is our only experience of hepatic granulomas in a patient with HCV infection unrelated to HIV infection, drugs or drug abuse (Figure 1). In this patient, in the open liver biopsy the hallmark histological changes of liver were the presence of epithelioid granulomas with central necrosis encircled by lymphocytes and fibrosis. No birefringent material or bile extravasations were detected. No acid-fast organism (AFO) was demonstrated. However, the morphological changes were suggestive of tuberculosis granulomas. Emile et al.17 described five patients in whom no AFOs were demonstrated.

Figure 1.

Hepatic granuloma, with central necrosis.

(0.15MB).

Both tuberculosis and HCV infections are diseases of global distribution, with high prevalence and with the characteristics of epidemics and endemic diseases. The presence of HCV infection and epithelioid granulomas in liver without any AFO demonstrated by histological techniques requires further study with polymerase chain reaction (PCR) technique to eliminate the other possible causes.

References
[1.]
Ishak K.G., Zimmerman H.J..
Drug-induced and toxic granulomatous hepatitis.
Baillieres Clin. Gastroenterol, 2 (1988), pp. 463-480
[2.]
Ryan B.M., McDonald G.S., Pilkington R., Kelleher D..
The development of hepatic granulomas following interferon-alpha 2b therapy for chronic hepatitis C infection.
Eur J Gastroenterol Hepatol, 10 (1998), pp. 349-351
[3.]
Murthy B.V.R., Pereira B.J..
A 1990s perspective of hepatitis C, human immunodeficiency virus, and tuberculosis infections in dialysis patients.
Semin Nephrol, 17 (1997), pp. 346-363
[4.]
Bach N., Thung S.N., Schaffner F..
The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis.
Hepatology, 15 (1992), pp. 572-777
[5.]
Scheuer P.J..
Classification of chronic viral hepatitis: a need for reassessment.
J Hepatol, 13 (1991), pp. 372-374
[6.]
Scheuer P.J., Ashrafzadeh P., Sherlock S., Brown D., Dusheiko G.M..
The pathology of hepatitis C.
Hepatology, 15 (1992), pp. 567-571
[7.]
Ishak K.G..
Chronic hepatitis: morphology and nomenclature.
Mod Pathol, 7 (1994), pp. 690-713
[8.]
Arista-Nasr J., Pichardo-Bahena R., Castaneda B., Lisker M., Keirns C..
Hepatitis C: a disease with a wide morphological spectrum?.
J Clin Gastroenterol, 22 (1996), pp. 121-125
[9.]
Knodell R.G., Conrad M.E., Ishak K.G..
Development of chronic liver disease after acute non-A non-B post-transfusion hepatitis.
Gastroenterology, 72 (1977), pp. 902-909
[10.]
Dienes H.P., Popper H., Arnold W., Lobeck H..
Histologic observations in human hepatitis non-A non-B.
Hepatology, 2 (1982), pp. 562-571
[11.]
Bianchi L., Desmet V.J., Popper H., Scheuer P.J., Aledort L.M., Berk P.D..
Histologic patterns of liver disease in hemophiliacs, with special reference to morphologic characteristics of non-A, non-B hepatitis.
Semin. Liver Dis, 7 (1987), pp. 203-209
[12.]
Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M..
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.
Science, 21 (1989), pp. 359-362
[13.]
Kuo G., Choo Q.L., Alter H.J., Gitnick G.L., Redeker A.G., Purcell R.H., Miyamura T., et al.
An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.
Science, 244 (1989), pp. 362-364
[14.]
Bedossa P..
Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C.
The French METAVIR Cooperative Study Group. Hepatology, 20 (1994), pp. 15-20
[15.]
Scheuer P.J..
Chronic hepatitis: what is activity and how should it be assessed?.
Histopathology, 30 (1997), pp. 103-105
[16.]
Barcena R., Sanroman A.L., Del Campo S., Garcia M., Moreno A., De Vicente E., Candela A..
Posttransplant liver granulomatosis associated with hepatitis C?.
Transplantation, 65 (1998), pp. 1494-1495
[17.]
Emile J.F., Sebagh M., Feray C., David F., Reynes M..
The presence of epithelioid granulomas in hepatitis C virus-related cirrhosis.
Hum Pathol, 24 (1993), pp. 1095-1097
Copyright © 2002. Fundación Clínica Médica Sur, A.C.
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos